A real-world analysis of second-line treatment option, gemcitabine plus anlotinib and anti-PD1, in advanced pancreatic cancer
| Autor: | Fan, Mengjiao, Ma, Yue, Deng, Guochao, Si, Haiyan, Jia, Ru, Wang, Zhikuan, Dai, Guanghai |
|---|---|
| Zdroj: | In Pancreatology June 2024 24(4):579-583 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect